Annexon (ANNX) announced that it has commenced an underwritten public offering of $75M of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. Goldman Sachs & Co., TD Cowen and Wells Fargo Securities are acting as joint book-running managers for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences: Promising Advancements in Late-Stage Complement Inhibitors Drive Buy Rating
- Positive Investment Outlook for Annexon Biosciences Driven by Financial Stability and Key Pipeline Developments
- Annexon Biosciences Reports Increased R&D Expenses
- Annexon reports Q3 EPS (37c), consensus (34c)
- ANNX Upcoming Earnings Report: What to Expect?